Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data.

Digestive diseases and sciences - 1 Sept 2022

Howden Colin W, Sheldon Kely L, Almenoff June S, Chey William D

Abstract excerpt

BACKGROUND: Helicobacter pylori (H. pylori) infects ~ 35% of Americans and can lead to serious sequelae if left untreated. Growing evidence indicates that clarithromycin-based therapies (CBT) are becoming increasingly ineffective for treating H. pylori infection. RHB-105 was approved by the US Food and Drug Administration in 2019 for the treatment of H. pylori infection in adults. AIMS: The primary aim of this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amoxicillin
Share to Clarithromycin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Cytochrome P-450 CYP2C19

Share to Helicobacter Infections

Share to Helicobacter pylori

Share to Physicians

Share to Proton Pump Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 34862940
DOI: 10.1007/s10620-021-07323-5
PMCID: PMC9352601

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data.PMID 34862940Read ↗

Helicobacter pylori Eradication Treatment in Ireland from 2012 to 2022: A Repeated Cross-sectional StudySemantic proximity Read ↗

Current and future insights in H. pylori eradication regimens: the need of tailoring therapy.Semantic proximity Read ↗

Challenges of Treating a <em>Helicobacter pylori </em>Infections following the COVID-19 Pandemic in Croatia: A ReviewSemantic proximity Read ↗

Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.Semantic proximity Read ↗

Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial.Semantic proximity Read ↗

Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.Semantic proximity Read ↗

Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.Semantic proximity Read ↗

Pharmacogenomics-based treatment of Helicobacter pylori infection.Semantic proximity Read ↗

Hp-normogram (normo-graham) for Assessing the Outcome of H. pylori Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype.Semantic proximity Read ↗

New concepts of resistance in the treatment of Helicobacter pylori infections.Semantic proximity Read ↗

Optimizing the Routine Use of Clinical Guidelines by Addition of Supplements (Probiotics and/or Bismuth) to <em>Helicobacter pylori</em> Eradication Protocols in a Clarithromycin Resistant and Tetracycline/Bismuth Naive Area: A Real-World Data Retrospective Analys of 402 Cases (2016-24) in a Single Gastroenterology UnitSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.